Chemistry:BMB-201

From HandWiki

BMB-201 is a serotonin 5-HT2A and 5-HT2C receptor agonist described as a non-hallucinogenic psychoplastogen which is under development for the treatment of depression, anxiety, pain, and other indications.[1][2][3][4][5] Its route of administration is unspecified.[1]

Pharmacology

BMB-201 is a prodrug of another compound known as BMB-A39a.[4][5] It acts as a biased partial agonist of the serotonin 5-HT2A and 5-HT2C receptors.[2][3][4][5][6] BMB-A39a is less efficacious in activating Gq signaling at the serotonin 5-HT2A and 5-HT2C receptors compared to psilocin (Emax = 68% vs. 82% at 5-HT2A and 79% vs. 95% at 5-HT2C for BMB-201 and psilocin, respectively).[5] The EC50 value of BMB-A39a in activating the serotonin 5-HT2C receptor is around 10-fold higher than for activating the 5-HT2A receptor (EC50 = 6.7 nM and 71.2 nM, respectively).[5]

In addition to the serotonin 5-HT2A and 5-HT2C receptors, BMB-A39a is a potent partial agonist of the serotonin 5-HT1F and 5-HT6 receptors.[4][6] It shows minimal or negligible activity in activating the serotonin 5-HT2B receptor (Emax < 20%) and does not activate other serotonin receptors.[4][5][6]

BMB-201 is said to have minimal or absent psychedelic effects due to its reduced serotonin 5-HT2A receptor intrinsic activity but to potently induce neuroplasticity.[4][5] It has been reported to show effectiveness in animal models of depression, anxiety, pain, and substance use disorder.[4][7][5]

Chemistry

7-Methylpsilocin, a lead compound with the same in-vitro pharmacology as BMB-A39a patented by Bright Minds Biosciences.[8][9] 7-Methyl­psilocybin was also patented.[9]

The exact chemical structure of BMB-201 does not yet appear to have been disclosed.[1][2][3][6] However, it is known to be a tryptamine derivative.[6] In addition, Bright Mind Biosciences has patented tryptamines and prodrugs as serotonin 5-HT2 receptor modulators.[9][10][11]

Research

BMB-201 is under development by Bright Minds Biosciences.[1][2][3] As of September 2025, it is in the preclinical research stage of development for the treatment of depressive disorders and pain.[1][2][3]

See also

References

  1. ↑ 1.0 1.1 1.2 1.3 1.4 "BMB 201". 10 September 2025. https://adisinsight.springer.com/drugs/800080130. 
  2. ↑ 2.0 2.1 2.2 2.3 2.4 "Delving into the Latest Updates on BMB-201 with Synapse". 29 October 2024. https://synapse.patsnap.com/drug/6842dbd395934d75aeaf38cf4dbeb43d. 
  3. ↑ 3.0 3.1 3.2 3.3 3.4 "BMB-201 Drug Profile". https://pryzm.ozmosi.com/product/bmb-201. 
  4. ↑ 4.0 4.1 4.2 4.3 4.4 4.5 4.6 "Novel 5-HT2A/2C mixed and partial agonist and its efficacy in preclinical pain models". Society for Neuroscience 2024 Annual Meeting, Chicago, October 5-9. October 2024. https://brightmindsbio.com/wp-content/uploads/2024/10/BMB-201-poster-PSPP-final.pdf. 
  5. ↑ 5.0 5.1 5.2 5.3 5.4 5.5 5.6 5.7 "Bright Minds Investor Deck". Bright Minds Biosciences Inc.. September 2024. https://brightmindsbio.com/wp-content/uploads/2024/09/BMB_investor_deck_September.pdf. 
  6. ↑ 6.0 6.1 6.2 6.3 6.4 "Overview of Bright Minds Biosciences: Pioneering Serotonin Pharmacology". 2025 AES Annual Meeting, December 5–9, Atlanta, Georgia. 7 December 2025. https://brightmindsbio.com/wp-content/uploads/2025/12/1.-Overview-of-Bright-Minds-Biosciences.-Pioneering-Serotonin-Pharmacology-_compressed.pdf. 
  7. ↑ "Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models". 17 October 2024. https://www.biospace.com/press-releases/bright-minds-biosciences-proprietary-compound-bmb-201-5-ht2c-2a-mixed-agonist-demonstrated-similar-efficacy-to-morphine-in-preclinical-pain-models. 
  8. ↑ "3-[2-(Dimethylamino)ethyl-7-methyl-1H-indol-4-ol"]. https://pubchem.ncbi.nlm.nih.gov/compound/166138173. 
  9. ↑ 9.0 9.1 9.2 "Heterocyclic compounds and methods of preparation thereof". 25 May 2022. https://patents.google.com/patent/WO2022246554A1/en. 
  10. ↑ "Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants". Chem Rev 124 (1): 124–163. January 2024. doi:10.1021/acs.chemrev.3c00375. PMID 38033123. "A recent patent from Bright Minds Bioscience disclosed a series of psilocin analogues with alkyl substitutions on the indole nitrogen, exemplified by compounds 13−16. 137 Among them, compounds 13−15 showed significantly decreased functional activities (13, EC50 = 196 nM, Emax = 65%; 14, EC50 = 188 nM, Emax = 48%; 15, EC50 = 1803 nM, Emax = 18%) compared to that of psilocin (EC50 = 8.34 nM at 5-HT2AR) in the Gq dissociation BRET assay, although all of them displayed excellent potency at 5-HT2CR and high selectivity against the 5-HT2BR. Compound 16, which contains a cyclopropylmethyl substitution on the indole nitrogen, exhibited potent partial agonist activity (EC50 = 28 nM, Emax = 29%) at the rat 5- HT2AR.137 No animal behavioral data have been reported on these compounds yet.". 
  11. ↑ "3-(2-(aminoethyl)-indol-4-ol derivatives, methods of preparation thereof, and the use as 5-ht2 receptor modulators". 12 March 2021. https://patents.google.com/patent/WO2021179091A1/en. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:BMB-201&oldid=4308690"